Linkage of a tumor immune function and cell cycle de-regulation via a gene regulatory network subcircuit

Molecular Immunology

Volumn 46, Issue 4, 2009, Pages 569-575

  Xu, Lijun ^a   Niesen, Melissa I ^a   Blanck, George ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

CIITA; Gene regulatory network subcircuits; HLA DR; Oct 1; Retinoblastoma protein

Indexed keywords

BINDING PROTEIN;

ARTICLE; CARCINOGENESIS; CELL CYCLE REGULATION; CELL FATE; CELL MATURATION; CONTROLLED STUDY; GENE CONTROL; GENE REGULATORY NETWORK; GROWTH REGULATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PHENOTYPE; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR IMMUNITY;

CELL CYCLE; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; NEOPLASMS; ORGANIC CATION TRANSPORTER 1; PROMOTER REGIONS, GENETIC; YY1 TRANSCRIPTION FACTOR;

ANIMALIA;

EID: 58249119590     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.07.035     Document Type: Article

References (26)

1. Armstrong T.D., Clements V.K., Martin B.K., Ting J.P., and Ostrand-Rosenberg S. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 6886-6891
2. Armstrong T.D., Clements V.K., and Ostrand-Rosenberg S. Class II-transfected tumor cells directly present endogenous antigen to CD4+ T cells in vitro and are APCs for tumor-encoded antigens in vivo. J. Immunother. 21 (1998) 218-224
3. Berry D.E., Lu Y., Schmidt B., Fallon P., O'Connell C., Hu S.-X., Xu H.-J., and Blanck G. Retinoblastoma protein inhibits IFN-gamma induced apoptosis. Oncogene 12 (1996) 1809-1819
4. Blanck G. Mutations and regulatory anomalies effecting tumor cell immune functions. Cancer Immunol. Immunother. 53 (2004) 1-16
5. Chopin D., Barei-Moniri R., Maille P., Frere-Belda M.A., Muscatelli-Groux B., Merendino N., Lecerf L., Stoppacciaro A., and Velotti F. Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. Am. J. Pathol. 162 (2003) 1139-1149
6. Deffrennes V., Vedrenne J., Stolzenberg M.C., Piskurich J., Barbieri G., Ting J.P., Charron D., and Alcaide-Loridan C. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter. J. Immunol. 167 (2001) 98-106
7. Ghosh N., Piskurich J.F., Wright G., Hassani K., Ting J.P.Y., and Wright K. A novel element and a TEF-2-like element activate the major histocompatibility complex class II transactivator in B-lymphocytes. J. Biol. Chem. 274 45 (1999) 32342-32350
8. Goodwin B., Hongkang X., Tejiram R., Eason D., Ghosh N., Wright K., Nagarajan U., Boss J., and Blanck G. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines. Cell Growth Diff. 12 (2001) 327-335
9. Gourley T.S., and Chang C.H. Cutting edge: the class II transactivator prevents activation-induced cell death by inhibiting Fas ligand gene expression. J. Immunol. 166 (2001) 2917-2921
10. Gronroos E., Terentiev A.A., Punga T., and Ericsson J. YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 12165-12170
11. Jordanova E.S., Philippo K., Giphart M.J., Schuuring E., and Kluin P.M. Mutations in the HLA class II genes leading to loss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma. Immunogenetics 55 (2003) 203-209
12. LaBella F., Sive H.L., Roeder R., and Heintz N. Cell cycle regulation of a human histone H2B gene is mediated by the H2B subtype-specific consensus element. Genes Dev. 2 (1988) 32-39
13. Le E., Zhang H., and Blanck G. CIITA transformation rescues the apoptotic function of MHC class II in melanoma cells. Anticancer Res. 25 (2005) 3889-3892
14. Maas S., Warskulat U., Steinhoff C., Mueller W., Grimm M.O., Schulz W.A., and Seifert H.H. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status. Urology 63 (2004) 392-397
15. Magner W.J., Kazim A.L., Stewart C., Romano M.A., Catalano G., Grande C., Keiser N., Santaniello F., and Tomasi T.B. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J. Immunol. 165 (2000) 7017-7024
16. Martins I., Deshayes F., Baton F., Forget A., Ciechomska I., Sylla K., Aoudjit F., Charron D., Al Daccak R., and Alcaide-Loridan C. Pathologic expression of MHC class II is driven by mitogen-activated protein kinases. Eur. J. Immunol. 37 (2007) 788-797
17. Muhlethaler-Mottet A., Otten L.A., Steimle V., and Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J. 16 (1997) 2851-2860
18. Murphy S. Differential in vivo activation of the class II and class III snRNA genes by the POU-specific domain of Oct-1. Nucleic Acids Res. 25 (1997) 2068-2076
19. Osborne A., Zhang H., Yang W.M., Seto E., and Blanck G. Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chromatin conformation. Mol. Cell Biol. 21 (2001) 6495-6506
20. Osborne A.R., Zhang H., Fejer G., Palubin K.M., Niesen M.I., and Blanck G. Oct-1 maintains an intermediate, stable state of HLA-DRA promoter repression in Rb-defective cells: an Oct-1-containing repressosome that prevents NF-Y binding to the HLA-DRA promoter. J. Biol. Chem. 279 (2004) 28911-28919
21. Shi B., Vinyals A., Alia P., Broceno C., Chen F., Adrover M., Gelpi C., Price J.E., and Fabra A. Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription Implication of CIITA in tumor and metastasis development. Int. J. Biochem. Cell Biol. 38 (2006) 544-562
22. Smith J., Theodoris C., and Davidson E.H. A gene regulatory network subcircuit drives a dynamic pattern of gene expression. Science 318 (2007) 794-797
23. Sotomayor E.M., Borrello I., Tubb E., Rattis F., Bien H., Lu Z., Fein S., Schoenberger S., and Levitsky H.I. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 5 (1999) 780-787
24. Steimle V., Siegrist C.A., Mottet A., Lisowska-Grospierre B., and Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 265 (1994) 106-109
25. Sui G., Affar e.B., Shi Y., Brignone C., Wall N.R., Yin P., Donohoe M., Luke M.P., Calvo D., Grossman S.R., and Shi Y. Yin Yang 1 is a negative regulator of p53. Cell 117 (2004) 859-872
26. Zhang H., Shepherd A.T., Eason D.D., Wei S., Diaz J.I., Djeu J.Y., Wu G.D., and Blanck G. Retinoblastoma protein expression leads to reduced Oct-1 DNA-binding activity and enhances interleukin-8 expression. Cell Growth Diff. 10 (1999) 457-465